Related Experiment Video
Updated: Jun 12, 2026

10:54
Conventional Repetitive Transcranial Magnetic Stimulation for Depression: A Step-by-Step Protocol
Published on: November 21, 2025
Should we stop using tricyclic antidepressants in pregnancy?
Psychological Medicine
|June 17, 2010
Summary
Tricyclic antidepressants may not be the safest option during pregnancy. A Swedish study found similar or worse outcomes for babies exposed to tricyclics compared to selective serotonin reuptake inhibitors.
Area of Science:
- Obstetrics and Gynecology
- Perinatal Psychiatry
- Pharmacology
Background:
- A Swedish study analyzed data from approximately 15,000 women and their babies regarding antidepressant use during pregnancy (1995-2007).
- The study investigated pregnancy and teratogenic outcomes associated with antidepressant exposure.
Discussion:
- Outcomes after exposure to tricyclic antidepressants (TCAs) were found to be equal or worse than those from selective serotonin reuptake inhibitors (SSRIs) or other antidepressants.
- This challenges the long-held belief that TCAs are the safest antidepressant choice during pregnancy.
Key Insights:
- Pregnancy outcomes following TCA exposure are comparable or inferior to SSRI exposure.
- The 'perinatal myth' suggesting TCAs as the safest pregnancy choice is questioned by recent findings.
- Limited but available data suggest a need to re-evaluate TCA use in pregnant populations.
Outlook:
- Further research is needed to confirm these findings, given the relatively small number of women in some comparative studies.
- Clinical guidelines for antidepressant use during pregnancy may require revision based on emerging evidence.
- Future studies should focus on long-term developmental outcomes for infants exposed to different antidepressant classes in utero.
Related Concept Videos
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics
Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla. Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...